Insulin vs Glucagon: A Technical Pros and Cons Analysis
Abstract: This technical analysis compares insulin and glucagon as therapeutic peptides, evaluating their mechanisms, applications, and market dynamics. Insulin, a 51-amino-acid anabolic hormone, excels in glucose uptake but risks hypoglycemia; glucagon (29 amino acids) counteracts hypoglycemia but has limited stability. The global peptide market, valued at $40.6B in 2023 (Grand View Research), shows insulin dominating diabetes care (60% share) while glucagon gains in emergency kits. Key brand comparisons (Novo Nordisk vs. Eli Lilly) highlight formulation advantages (e.g., faster-acting analogs). Regulatory certifications (FDA, EMA) and cold-chain logistics (2-8°C) are critical. Selection criteria prioritize purity (>98%), bioactivity, and manufacturer GMP compliance. Industry trends favor dual-action peptides and oral delivery innovations.